LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article: Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy.

    Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández-Garcia, Miguel Teodoro / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabela / Mercadal, Santiago / Galeo, Andrea / Jiménez, Javier López / Moraleda, José M / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /
    Palomera, Luis / Jarque, Isidro / Rodriguez, Antonia / Lorza, Leyre / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / José Lahuerta, Juan

    Hematology/oncology and stem cell therapy

    2019  Volume 12, Issue 4, Page(s) 194–203

    Abstract: Objective/background: Patients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in ... ...

    Abstract Objective/background: Patients with follicular lymphoma (FL) with early therapy failure (ETF) within 2 years of frontline therapy have poor overall survival (OS). We recently reported the results of autologous stem cell transplantation (ASCT) in patients from the Grupo Español de Linfomas y Trasplantes de Médula Ósea (GELTAMO) registry treated with rituximab prior to ASCT and with ETF after first-line immunochemotherapy, leading to 81% 5-year OS since ASCT. We explored whether ASCT is also an effective option in the pre-rituximab era-that is, in patients treated in induction and rescued only with chemotherapy.
    Methods: ETF was defined as relapse/progression within 2 years of starting first-line therapy. We identified two groups: the ETF cohort (n = 87) and the non-ETF cohort (n = 47 patients receiving ASCT but not experiencing ETF following first-line therapy).
    Results: There was a significant difference in 5-year progression-free survival between the ETF and non-ETF cohorts (43% vs. 57%, respectively; p = .048). Nevertheless, in patients with ETF with an interval from first relapse after primary treatment to ASCT of <1 year, no differences were observed in 5-year progression-free survival (48% vs. 66%, respectively; p = .44) or in 5-year OS (69% vs. 77%, p = .4). Patients in the ETF cohort transplanted in complete remission showed a plateau in the OS curves, at 56%, beyond 13.7 years of follow-up.
    Conclusion: ASCT may be a curative option for ETF in patients who respond to rescue chemotherapy, without the need for immunotherapy or other therapies, and should be considered as an early consolidation, especially in patients with difficult access to rituximab.
    MeSH term(s) Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Registries ; Rituximab/administration & dosage ; Stem Cell Transplantation ; Survival Rate
    Chemical Substances Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2019-07-09
    Publishing country England
    Document type Journal Article
    ZDB-ID 2651893-4
    ISSN 1658-3876
    ISSN 1658-3876
    DOI 10.1016/j.hemonc.2019.06.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Shock séptico con purpura fulminans por Capnocytophaga canimorsus.

    González-García, Alberto / Ferreiro, José Javier / López-Lopategui, Ma Carmen / Zabarte, Mercedes

    Enfermedades infecciosas y microbiologia clinica

    2004  Volume 22, Issue 5, Page(s) 309–310

    Title translation Septic shock with purpura fulminans due to Capnocytophaga canimorsus.
    MeSH term(s) Acute Kidney Injury/etiology ; Capnocytophaga/isolation & purification ; Gram-Negative Bacterial Infections/complications ; Gram-Negative Bacterial Infections/microbiology ; Humans ; Male ; Middle Aged ; Pleural Effusion/etiology ; Purpura, Schoenlein-Henoch/etiology ; Shock, Septic/complications ; Shock, Septic/microbiology
    Language Spanish
    Publishing date 2004-07-01
    Publishing country Spain
    Document type Case Reports ; Letter
    ZDB-ID 1070941-1
    ISSN 1578-1852 ; 0213-005X
    ISSN (online) 1578-1852
    ISSN 0213-005X
    DOI 10.1016/s0213-005x(04)73097-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Secondary malignancies and survival outcomes after autologous stem cell transplantation for follicular lymphoma in the pre-rituximab and rituximab eras: a long-term follow-up analysis from the Spanish GELTAMO registry.

    Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Hernández-Garcia, Miguel Teodoro / Novelli, Silvana / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabella / Mercadal, Santiago / Galeo, Andrea / Jiménez, Javier López / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura / Palomera, Luis /
    Jarque, Isidro / Martínez-Sánchez, Pilar / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

    Bone marrow transplantation

    2018  Volume 53, Issue 6, Page(s) 780–783

    MeSH term(s) Female ; Follow-Up Studies ; Hematopoietic Stem Cell Transplantation/adverse effects ; Hematopoietic Stem Cell Transplantation/methods ; Humans ; Lymphoma, Follicular/complications ; Lymphoma, Follicular/pathology ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Neoplasms, Second Primary ; Registries ; Retrospective Studies ; Rituximab ; Survival Analysis ; Transplantation, Autologous/adverse effects ; Transplantation, Autologous/methods
    Chemical Substances Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2018-01-23
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/s41409-018-0096-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Autologous stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue treatment.

    Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández-Garcia, Miguel Teodoro / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabela / Mercadal, Santiago / Galeo, Andrea / Jiménez, Javier López / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /
    Palomera, Luis / Jarque, Isidro / Martínez-Sánchez, Pilar / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

    Hematological oncology

    2018  Volume 36, Issue 5, Page(s) 765–772

    MeSH term(s) Adult ; Aged ; Autografts ; Disease-Free Survival ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/therapy ; Male ; Middle Aged ; Registries ; Rituximab ; Spain/epidemiology ; Survival Rate
    Chemical Substances Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2018-09-12
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Multicenter Study
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.2553
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.

    Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández, Miguel T / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabela / Mercadal, Santiago / Galego, Andrea / Jiménez, Javier López / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /
    Palomera, Luis / Jarque, Isidro / Coria, Erika / Rodriguez, Antonia / Martín, Alejandro / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

    Cancer medicine

    2017  Volume 6, Issue 12, Page(s) 2766–2774

    Abstract: Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier ... ...

    Abstract Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the setting of first-line chemo-/immunotherapy, as surrogates for OS-progression-free survival (PFS) status at 24 months (PFS24) and complete response at 30 months (CR30) post-ASCT. We also have investigated the clinical features of patients with early progression after ASCT. Data were available for 626 chemosensitive FL patients who received ASCT between 1989 and 2007. Median follow-up was 12.2 years from ASCT. In the PFS24 analysis, 153 (24%) patients progressed within 24 months and 447 were alive and progression-free at 24 months post-ASCT (26 who died without disease progressions within 24 months were excluded). Early progression was associated with shorter OS (hazard ratio [HR], 6.8; P = 0.00001). In the subgroup of patients who received an ASCT in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% CI, 3.9-30.2; P < 0.00001). In the CR30 analysis, 183 of 596 (31%) response-evaluable patients progressed/died with 30 months post-ASCT. The absence of CR30 was associated with shorter OS (HR, 7.8; P < 0.00001), including in patients with prior rituximab (HR, 8.2). PFS24 and CR30 post-ASCT are associated with poor outcomes and should be primary end points. Further research is needed to identify this population to be offered alternative treatments.
    MeSH term(s) Adolescent ; Adult ; Aged ; Antineoplastic Agents/therapeutic use ; Databases, Factual ; Disease Progression ; Disease-Free Survival ; Endpoint Determination ; Female ; Humans ; Immunotherapy/methods ; Kaplan-Meier Estimate ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/surgery ; Male ; Middle Aged ; Proportional Hazards Models ; Registries ; Retrospective Studies ; Risk Factors ; Spain ; Stem Cell Transplantation/adverse effects ; Stem Cell Transplantation/mortality ; Time Factors ; Transplantation, Autologous ; Treatment Outcome ; Young Adult
    Chemical Substances Antineoplastic Agents
    Language English
    Publishing date 2017-10-26
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ISSN 2045-7634
    ISSN (online) 2045-7634
    DOI 10.1002/cam4.1217
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.

    Jiménez-Ubieto, Ana / Grande, Carlos / Caballero, Dolores / Yáñez, Lucrecia / Novelli, Silvana / Hernández-Garcia, Miguel Teodoro / Manzanares, María / Arranz, Reyes / Ferreiro, José Javier / Bobillo, Sabella / Mercadal, Santiago / Galeo, Andrea / López Jiménez, Javier / Moraleda, José María / Vallejo, Carlos / Albo, Carmen / Pérez, Elena / Marrero, Carmen / Magnano, Laura /
    Palomera, Luis / Jarque, Isidro / Martínez-Sánchez, Pilar / Martín, Alejandro / Coria, Erika / López-Guillermo, Armando / Salar, Antonio / Lahuerta, Juan José

    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

    2017  Volume 23, Issue 10, Page(s) 1631–1640

    Abstract: High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a ... ...

    Abstract High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a rituximab-free chemotherapy regimen. A total of 655 patients with FL were reported to the Spanish GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) registry and underwent first ASCT between 1989 and 2007. A total of 203 patients underwent ASCT in first complete response (CR1), 174 in second complete response (CR2), 28 in third complete response (CR3), 140 in first partial response (PR1), 81 in subsequent PR, and 29 with resistant/refractory disease; 184 patients received rituximab before ASCT. With a median follow-up of 12 years from ASCT, median progression-free survival (PFS) and overall survival (OS) were 9.7 and 21.3 years, respectively. Actuarial 12-year PFS and OS were 63% (95% confidence interval [CI], 58%-68%) and 73% (95% CI, 68%-78%), respectively, for patients in CR (with a plateau in the curve beyond 15.9 years), 25% (95% CI, 19%-28%) and 49% (95% CI 42%-56%), respectively, for patients in PR, and 23% (95% CI, 8%-48%) and 28% (95% CI, 9%-45%), respectively, for patients with resistant/refractory disease (P < .001). In patients who received rituximab before ASCT, the estimated 9-year PFS and OS from ASCT were 59.5% (95% CI, 51%-67%) and 75% (95% CI, 68%-83%), respectively. Interestingly, for patients who underwent transplantation in CR ≥2 or PR ≥2 who had received rituximab before ASCT (n = 90), 9-year PFS and OS were 61% (95% CI, 51%-73%) and 75% (95% CI, 65%-80%), respectively, with no relapses occurring beyond 5.1 years after ASCT. The cumulative incidence of second malignancies in the global series was 6.7% at 5 years and 12.8% at 10 years. This analysis strongly suggests that ASCT is a potentially curative option for eligible patients with FL. In the setting of relapse, it is of especial interest in pretransplantation rituximab-sensitive patients with FL.
    Language English
    Publishing date 2017-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1474865-4
    ISSN 1523-6536 ; 1083-8791
    ISSN (online) 1523-6536
    ISSN 1083-8791
    DOI 10.1016/j.bbmt.2017.05.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top